Skip to content

Psilocybin research published in 2015

31 studies whose primary subject is psilocybin were published in 2015, up from 20 in 2014. Newest first. Back to the psilocybin overview

Studies

Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts

Drug and Alcohol Dependence November 1, 2015 Albert Garcia‐romeu, Tehseen Noorani, Roland R. Griffiths et al. 6 citations

Aims: We assessed long-term (>12 months) outcomes of psilocybin-facilitated smoking cessation, and qualitatively analyzed participants’ accounts to inform potential psychological mechanisms of treatment efficacy. Methods: Fifteen individuals who completed a pilot study of psilocybin-facilitated smoking cessation were invited for a long-term follow-up. Eleven (73%) returned and were interviewed...

DOI: 10.1016/j.drugalcdep.2015.07.1130 (opens in new tab) Endocannabinoid system Cannabinoid receptor 2-arachidonoylglycerol Norepinephrine +5

Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey

Journal of Psychoactive Drugs October 20, 2015 Emmanuelle A. D. Schindler, Christopher Gottschalk, Marsha J. Weil et al. 104 citations

Cluster headache is one of the most debilitating pain syndromes. A significant number of patients are refractory to conventional therapies. The Clusterbusters.org medication use survey sought to characterize the effects of both conventional and alternative medications used in cluster headache. Participants were recruited from cluster headache websites and headache clinics. The final analysis...

Sex differences and serotonergic mechanisms in the behavioural effects of psilocin

Behavioural Pharmacology October 13, 2015 Filip Tylš, Tomáš Páleníček, Lukáš Kadeřábek et al. 86 citations

Psilocybin has recently attracted a great deal of attention as a clinical research and therapeutic tool. The aim of this paper is to bridge two major knowledge gaps regarding its behavioural pharmacology – sex differences and the underlying receptor mechanisms. We used psilocin (0.25, 1 and 4 mg/kg), an active metabolite of psilocybin, in two behavioural paradigms – the open-field test and...

Return of the lysergamides. Part I: Analytical and behavioural characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD)

Drug Testing and Analysis October 12, 2015 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 79 citations

1‐Propionyl‐ d ‐lysergic acid diethylamide hemitartrate (1P‐LSD) has become available as a ‘research chemical’ in the form of blotters and powdered material. This non‐controlled derivative of d ‐lysergic acid diethylamide (LSD) has previously not been described in the published literature despite being closely related to 1‐acetyl‐LSD (ALD‐52), which was developed in the 1950s. This study...

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Journal of Psychopharmacology October 6, 2015 Frederick S. Barrett, Matthew W Johnson, Roland R. Griffiths 634 citations

The 30-item revised Mystical Experience Questionnaire (MEQ30) was previously developed within an online survey of mystical-type experiences occasioned by psilocybin-containing mushrooms. The rated experiences occurred on average eight years before completion of the questionnaire. The current paper validates the MEQ30 using data from experimental studies with controlled doses of psilocybin. Data...

DOI: 10.1177/0269881115609019 (opens in new tab) Psilocybin Mysticism Structural equation modeling Hallucinogen +2

[Psilocybin - public available psychodysleptic].

September 7, 2015 Karolina Dydak, Mariola Śliwińska‐mossoń, Halina Milnerowicz 5 citations

Substances of plant origin have been used to induce hallucinations for a long time, in religious ceremonies and rituals as well as in pain relief. Psilocybin and psilocin naturally occur in the fungal genus Psilocybe. Due to the psychedelic effects and relative harmlessness of these substances and the fact that they do not cause physical addiction, psilocybin and psilocin recently have been...

Toxicology Rounds

Emergency Medicine News September 1, 2015 Leon Gussow

Figure: Phenethylamine, top left; 2C-I, top right; and 25I-NBOMe, below.FigureAt least 19 young people died between March 2012 and November 2013 from the so-called N-BOMB drugs, synthetic hallucinogens that can be deadlier than LSD, according to the U.S. Drug Enforcement Administration. Chemist Alexander Shulgin developed a series of hallucinogenic 2C drugs in the early 1970s by adding...

Psilocybin, psychological distress, and suicidality

Journal of Psychopharmacology September 1, 2015 Peter S. Hendricks, Matthew W Johnson, Roland R. Griffiths 107 citations

Hendricks et al. (2015) found that having ever used any classic psychedelic substance—namely, dimethyltryptamine (DMT), ayahuasca, lysergic acid diethylamide (LSD), mescaline, peyote or San Pedro, or psilocybin—was associated with a significantly reduced likelihood of past month psychological distress (weighted OR = . 81 (. 72–. 91)), past year suicidal thinking (weighted OR = . 86 (. 78–....

DOI: 10.1177/0269881115598338 (opens in new tab) Full text (opens in new tab) Psilocybin Psychological distress Hallucinogen Clinical psychology +1

The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity

NeuroImage: Clinical August 22, 2015 Rainer Kraehenmann, André Schmidt, Karl Friston et al. 107 citations

Stimulation of serotonergic neurotransmission by psilocybin has been shown to shift emotional biases away from negative towards positive stimuli. We have recently shown that reduced amygdala activity during threat processing might underlie psilocybin's effect on emotional processing. However, it is still not known whether psilocybin modulates bottom-up or top-down connectivity within the...

Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations

Psychopharmacology July 31, 2015 Michael Kometer, Thomas Pokorny, Erich Seifritz et al. 165 citations

RationaleDuring the last years, considerable progress has been made toward understanding the neuronal basis of consciousness by using sophisticated behavioral tasks, brain-imaging techniques, and various psychoactive drugs. Nevertheless, the neuronal mechanisms underlying some of the most intriguing states of consciousness, including spiritual experiences, remain unknown.ObjectivesTo elucidate...

Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain

Neuropharmacology July 18, 2015 Aisling Spain, Clare Howarth, Alexandre A. Khrapitchev et al. 45 citations

The development of pharmacological magnetic resonance imaging (phMRI) has presented the opportunity for investigation of the neurophysiological effects of drugs in vivo. Psilocin, a hallucinogen metabolised from psilocybin, was recently reported to evoke brain region-specific, phMRI signal changes in humans. The present study investigated the effects of psilocin in a rat model using phMRI and...

Restructuring consciousness –the psychedelic state in light of integrated information theory

Frontiers in Human Neuroscience June 12, 2015 Andrew R. Gallimore 52 citations

The psychological state elicited by the classic psychedelics drugs, such as LSD and psilocybin, is one of the most fascinating and yet least understood states of consciousness. However, with the advent of modern functional neuroimaging techniques, the effect of these drugs on neural activity is now being revealed, although many of the varied phenomenological features of the psychedelic state...

DOI: 10.3389/fnhum.2015.00346 (opens in new tab) Psilocybin Consciousness Integrated information theory Cognitive science +7

Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin

Human Brain Mapping May 22, 2015 Alexander V. Lebedev, Martin Lövdén, Gidon Rosenthal et al. 347 citations

Ego-disturbances have been a topic in schizophrenia research since the earliest clinical descriptions of the disorder. Manifesting as a feeling that one's "self," "ego," or "I" is disintegrating or that the border between one's self and the external world is dissolving, "ego-disintegration" or "dissolution" is also an important feature of the psychedelic experience, such as is produced by...

Psilocybin-containing mushrooms, upper palaeolithic rock art and the neuropsychological model

Rock Art Research May 1, 2015 Patricia A. Helvenston 2 citations

Two recent papers authored by Froese, Woodward and Ikegami present the neuropsychological model of Lewis-Williams and Dowson as if it had just been published. This paper corrects their distortions of the work of critics, including Helvenston and Bahn, addresses neuropsychological errors and discusses the complexities of psilocybin-containing mushrooms. It includes a discussion of the mushrooms...

The use of illicit drugs as self-medication in the treatment of cluster headache: Results from an Italian online survey

Cephalalgia April 22, 2015 Cherubino Di Lorenzo, Gianluca Coppola, Giorgio Di Lorenzo et al. 40 citations

Background Cluster headache (CH) patients often receive unsatisfactory treatment and may explore illicit substances as alternatives. We aimed to explore this use of illicit drugs for CH treatment. Methods We invited CH patients from an Internet-based self-help group to complete a questionnaire regarding their therapeutic use of illicit substances. Results Of the 54 respondents, 29 were...

Discovery of a new caerulescent Psilocybe mushroom in Germany: Psilocybe germanica sp.nov.

Drug Testing and Analysis March 31, 2015 Jochen Gartz, Georg Wiedemann 13 citations

Sixty years ago, the ethnomycologist R. G. Wasson discovered an ancient mushroom cult in Oaxaca, Mexico. 1, 2 The famous mycologist R. Heim classified the psychoactive mushroom species in the genera Psilocybe and the eminent natural product chemist Albert Hofmann published the isolation, structural elucidation and synthesis of the new alkaloids psilocybin and psilocin in 1958. These indole...

DOI: 10.1002/dta.1795 (opens in new tab) Psilocybin Mushroom Indole alkaloid Botany +1

Research on Acute Toxicity and the Behavioral Effects of Methanolic Extract from Psilocybin Mushrooms and Psilocin in Mice

Toxins March 27, 2015 О. В. Жук, Іzabela Jasicka-Misiak, Anna Poliwoda et al. 64 citations

The pharmacological activities and acute toxicity of the psilocin (PC) and dried residues of the crude extracts of psychotropic mushrooms were investigated in mice. The hallucinogenic substances were effectively isolated, by using methanol, from the species of Psilocybe semilanceata and Pholiotina cyanopus, that were collected in the north-east region of Poland. The chemical analysis of these...

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.

Journal of Psychopharmacology March 1, 2015 Peter S. Hendricks, Christopher B Thorne, C Brendan Clark et al. 377 citations

Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over...

The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-making

European Psychiatry March 1, 2015 Katrin H. Preller, Thomas Pokorny, Rainer Krähenmann et al. 20 citations

Social cognition is a crucial factor influencing development, progress, and treatment of psychiatric disorders. However, social cognition skills are insufficiently targeted by current treatment approaches. In particular, patients suffering from depression show an increased negative reaction to social exclusion and deficits in empathy. The 5HT-1A/2A receptor agonist psilocybin has previously...

Psychedelics not linked to mental health problems or suicidal behavior: A population study

Journal of Psychopharmacology March 1, 2015 Pål-ørjan Johansen, Teri Suzanne Krebs 300 citations

A recent large population study of 130,000 adults in the United States failed to find evidence for a link between psychedelic use (lysergic acid diethylamide, psilocybin or mescaline) and mental health problems. Using a new data set consisting of 135,095 randomly selected United States adults, including 19,299 psychedelic users, we examine the associations between psychedelic use and mental...